Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WSK-IM05 Combined With Tislelizumab as Neoadjuvant Therapy for HPV-Positive Oropharyngeal Squamous Cell Carcinoma
NCT07565740Phase 1Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- May 2026
- Primary completion
- May 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of WSK-IM05 in oropharyngeal squamous cell carcinoma (OPSCC) (3 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Dose-Limiting Toxicities at 21 days, Treatment-Related Adverse Events at 2 months and 1 more. Started May 2026; status: recruiting.
02
Drugs
WSK-IM05
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT07565740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07565740.